Jeremy Sugarman, MD, MPH, MA

Deputy Director for Medicine; Harvey M. Meyerhoff Professor of Bioethics and Medicine

Contact

1809 Ashland Ave.
Room 203
Baltimore, MD 21205
410-614-5634
jsugarman@jhu.edu
People
  • Deputy Director for Medicine
    Johns Hopkins Berman Institute of Bioethics
  • Harvey M. Meyerhoff Professor of Bioethics and Medicine
    Johns Hopkins Berman Institute of Bioethics
    Johns Hopkins School of Medicine
  • Professor of Health Policy and Management
    Johns Hopkins Bloomberg of Public Health

Jeremy Sugarman, MD, MPH, MA is the Harvey M. Meyerhoff Professor of Bioethics and Medicine, professor of medicine, professor of Health Policy and Management, and deputy director for medicine of the Berman Institute of Bioethics at the Johns Hopkins University. He is an internationally recognized leader in bioethics with particular expertise in applying empirical methods and evidence-based standards for evaluating and analyzing bioethical issues. His contributions to bioethics and policy include his work on the ethics of informed consent, umbilical cord blood banking, stem cell research, international HIV prevention research, global health and research oversight.

Read More

Dr. Sugarman is the author of over 350 articles, reviews and book chapters.  He has also edited or co-edited four books (Beyond Consent: Seeking Justice in Research; Ethics of Research with Human Subjects: Selected Policies and Resources; Ethics in Primary Care; and Methods in Medical Ethics).  Dr. Sugarman is on the editorial boards of several academic journals.

Dr. Sugarman consults and speaks internationally on a range of issues related to bioethics. He was senior policy and research analyst for the White House Advisory Committee on Human Radiation Experiments, consultant to the National Bioethics Advisory Commission, and Senior Advisor to the Presidential Commission for the Study of Bioethical Issues. He also served on the Maryland Stem Cell Research Commission.

He was the founding director of the Trent Center for Bioethics, Humanities and History of Medicine at Duke University where he was also a professor of medicine and philosophy. He was appointed as an Academic Icon at the University of Malaya and is a faculty affiliate of the Kennedy Institute of Ethics at Georgetown University.

Dr. Sugarman is currently a member of the Scientific and Research Advisory Board for the Canadian Blood Service and the Ethics and Public Policy Committees of the International Society for Stem Cell Research. He is co-chair of the Johns Hopkins’ Institutional Stem Cell Research Oversight Committee. In addition, he is chair of the Ethics Working Group of the HIV Prevention Trials Network and co-leads the Ethics and Regulatory Core of the NIH Health Care Systems Research Collaboratory.

Dr. Sugarman has been elected as a member of the American Society of Clinical Investigation, Association of American Physicians, and the National Academy of Medicine (formerly the Institute of Medicine). He is a fellow of the American Association for the Advancement of Science, the American College of Physicians and the Hastings Center. He also received a Doctor of Science, honoris causa, from New York Medical College.

Research Interests

  • Informed consent
  • Stem cell research
  • International HIV prevention research
  • HIV cure research
  • Global health
  • Emerging technologies
  • Research oversight
  • Methods in bioethics
  • Pragmatic clinical trials
  • Clinical trial design
  • Umbilical cord blood banking

Education

  • B.S., Duke University
  • M.D., Duke University School of Medicine
  • M.P.H., Johns Hopkins Bloomberg School of Public Health
  • M.A., Applied Ethics, Georgetown University

Activities

  • Co-Chair, Institutional Stem Cell Research Oversight Committee, Johns Hopkins University

Recent Publications

  • Sugarman J, Celum CL, Donnell D, Mayer KH. Ethical considerations for new HIV prevention trials. Lancet HIV 2019; 6:e489-e491. doi: 10.1016/S2352-3018(19)30184-5. PMID: 31256635.
  • Sugarman J, Barker RA, Charo RA. A professional standard for informed consent for stem cell therapies. JAMA 2019 Aug 12. doi:10.1001/jama.2019.11290. [Epub ahead of print]. PMID: 31403653.
  • Morain SR, Weinfurt K, Bollinger J, Geller G, Mathews DJ, Sugarman J. Ethics and collateral findings in pragmatic clinical trials. Am J Bioeth 2020; 20: 6-18. doi:10.1080/15265161.2020.1689031. PMID: 31896322.
  • Sugarman J, Bredenoord AL. Real-time ethics engagement in biomedical research. EMBO Rep 2020; 21 (2), e49919; doi: 10.15252/embr.201949919. PMID: 31944538. [Epub ahead of print].
  • Brown BJ, Sugarman J, for the HPTN Ethics Working Group. Why ethics guidance needs to be updated for contemporary HIV prevention research. J Int AIDS Soc 2020 May 23:e25500. doi: 10.1002/jia2.25500. PMID: 32406990.
  • Cox A, Sulkowski M, Sugarman J. Ethical and practical issues associated with the possibility of using controlled human infection trials in developing a Hepatitis C virus vaccine. Clin Infect Dis 2020;71:2986-2990. doi:10.1093/cid/ciaa640 [Epub ahead of print, 2020 May 22]. PMID: 32442262.
  • Dawson L, Benbow N, Fletcher FE, Kassaye S, Killelea A, Latham S, Lee LM, Leitner T, Little SJ, Mehta SR, Martinez O, Minalga B, Poon A, Rennie S, Sugarman J, Sweeney P, Torian LV, Wertheim JO. Addressing ethical challenges in US-based HIV phylogenetic research. J Infect Dis 2020;jiaa107. doi:10.1093/infdis/jiaa107 [Epub ahead of print, 2020 Jun 11]. PMID: 32525980.
  • Bloch EM, Gehrie EA, Ness PM, Sugarman J, Tobian AAAR. Blood transfusion safety in low-resourced countries: Aspiring to a higher standard. Ann Intern Med doi:10.7326/M20-0203. [Epub ahead of print, 2020 June 16]. PMID: 32539444.
  • Sugarman J, Carrithers J. Certificates of confidentiality and unexpected complications for pragmatic clinical trials. Learn Health Syst2020 Jul 14:4(2):e10238. doi:10.1002/lrh2.10238. PMID: 33889738.
  • Barnes M, Carrithers J, Sugarman J. Ethical and practical concerns about IRB restrictions on the use of research data. Ethics Hum Res2020;42:29-34. doi:10.1002/eahr.500072. PMID: 33136330.
  • Rennie S, Chege W, Schrumpf LA, Luna F, Klitzman R, Moseki E, Brown B, Wakefield S, Sugarman J. HIV prevention research and COVID-19: putting ethics guidance to the test. BMC Med Ethics 2021; 22. doi: 10.1186/s12910-021-00575-w. PMID: 33494754.
  • Matthews KRW, Iltis AS, Marquez NG, Wagner DS, Robert JS, de Melo-Martín I, Bigg M, Franklin S, Holm S, Metzler I, Molè MA, Taupitz J, Testa G, Sugarman J. Rethinking human embryo research policies. Hastings Cent Rep 2021;51:47-51. doi: 10.1002/hast.1215. PMID: 33630327.
  • Seaman S, Brown D, Eno A, Yu S, Massie AB, Tobian AAR, Durand CM, Segev DL, Wu AW, Sugarman J. Development of a Patient Reported Measure of Experimental Transplants with HIV and Ethics in the United States (PROMETHEUS). J Patient Rep Outcomes2021;5:28. doi: 10.1186/s41687-021-00297-y. PMID: 33738660.
  • Tackett S, Sugarman J, Ng CJ, Kamarulzaman A, Ali J. Developing a competency framework for health research ethics education and training. J Med Ethics doi: 10.1136/medethics-2021-107237. [Epub ahead of print 2021 Apr 2]. PMID: 33811112.
  • Lovell-Badge R, Anthony E, Barker RA, Bubela T, Brivanlou AH, Carpenter M, Charo RA, Clark A, Clayton E, Cong Y, Daley GQ, Fu J, Fujita M, Greenfield A, Goldman SA, Hill L, Hyun I, Isasi R, Kahn J, Kato K, Kim JS, Kimmelman J, Knoblich JA, Mathews D, Montserrat N, Mosher J, Munsie M, Nakauchi H, Naldini L, Naughton G, Niakan K, Ogbogu U, Pedersen R, Rivron N, Rooke H, Rossant J, Round J, Saitou M, Sipp D, Steffann J, Sugarman J, Surani A, Takahashi J, Tang F, Turner L, Zettler PJ, Zhai X. ISSCR guidelines for stem cell research and clinical translation: The 2021 update. Stem Cell Reports doi: 10.1016/j.stemcr.2021.05.012.
  • Zeps N, Lysaght T, Chadwick R, Erler A, Foo R, Giordano S, San Lai P, Schaefer GO, Xafis V, Chew WL, Sugarman J. Ethics and regulatory considerations for the clinical translation of somatic cell human epigenetic editing. Stem Cell Reports 202:S2213-6711(21)00310-6. doi: 10.1016/j.stemcr.2021.06.004. [Epub ahead of print Jun 29]. PMID: 34214486
  • Bollinger J, May E, Mathews D, Donowitz M, Sugarman J. Patients’ perspectives on the derivation and use of organoids. Stem Cell Reports 2021:S2213-6711(21)00329-5. doi: 10.1016/j.stemcr.2021.07.004. [Epub ahead of print Jul 19]. PMID: 34329595.
  • Weinfurt KP, Bollinger JM, May E, Geller G, Mathews DJH, Morain SR, Schmid L, Bloom DL, Sugarman J. Patients’ reactions to letters communicating collateral findings of pragmatic clinical trials: a national web-based survey. J Gen Intern Med doi: 10.1007/s11606-021-07087-8. [Epub ahead of print Aug 12]. PMID: 34383228.
  • Sugarman J, Donnell DJ, Hanscom B, McCauley M, Grinsztejn B, Landovitz RJ. Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial. Lancet HIV 2021; S2352-3018(21)00153-3. doi: 10.1016/S2352-3018(21)00153-3. [Epub ahead of print Aug 26]. PMID: 34454678.
  • Morain SR, Mathews DJH, Geller G, Bollinger J, Weinfurt K, Jarvik JG, May E, Sugarman J. Identification and management of pragmatic clinical trial collateral findings: a current understanding and directions for future research. Healthcare 2021;9:100586. doi: 10.1016/j.hjdsi.2021.100586. [Epub ahead of print Sep 29]
  • Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, Lambotte O, Lamplough R, Ndung’u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR; International AIDS Society (IAS) Global Scientific Strategy working group. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat Med 2021;27:2085-2098. doi: 10.1038/s41591-021-01590-5. Epub 2021 Dec 1. PMID: 34848888.

Related Projects

NIH Health Care System Research Collaboratory Regulatory/Ethics Core

Navigating regulatory and ethical complexities associated with pragmatic clinical trials in health care systems

PCORnet Ethics and Regulatory Task Force

Addressing the ethical and regulatory issues related to research that arise in PCORI’s work